Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplace
Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelberg AppWay marketplace, designed to empower eye care professionals and researchers with automated, quantitative insights into choroidal health from routine OCT scans.
According to Heidelberg, NMI-ChoroidAI leverages advanced machine learning to intelligently process SPECTRALIS OCT volume data, automatically segmenting the inner and outer choroidal boundaries and analyzing the choroidal vasculature. The system enables precise 3D segmentation and delivers comprehensive measurements of choroidal thickness, volume, and the Choroidal Vascularity Index (CVI). Results are presented in ETDRS grid format with detailed tabulated reports, designed for seamless integration into both clinical workflows and research protocols.
“Accurate assessment of the choroid is essential in understanding and managing retinal diseases such as AMD, CSCR, and pathological myopia. Manual segmentation is often time-consuming and subjective. With NMI-ChoroidAI, clinicians and researchers gain objective, reproducible, and fully automated analyses in a fraction of the time, enhancing both patient care and scientific discovery,” said Dr. Jay Chhablani, Professor of Ophthalmology at the University of Pittsburgh and Director of the Choroidal Analysis and Research Lab at UPMC Eye Center.
Developed by NetraMind Innovations, NMI-ChoroidAI aims to address critical challenges in choroid analysis. The solution provides AI-accelerated segmentation with clinician oversight, intuitive visualization tools, CVI heat mapping, and compatibility with HEYEX 2, transforming a previously tedious process into rapid, clinically valuable insight.
“At NetraMind Innovations, our mission is to push the boundaries of innovation in healthcare through advanced analytics,” added Dr. Chhablani. “With NMI-ChoroidAI on the Heidelberg AppWay platform, ophthalmologists and researchers can now unlock deeper insights into the choroid, helping to improve diagnostic confidence, streamline workflow, and accelerate research into ocular diseases.”
Experience NMI-ChoroidAI at AAO 2025
Attendees of the American Academy of Ophthalmology (AAO) annual meeting in Orlando (October 18-20, 2025) will have the opportunity to experience a live demonstration of NMI-ChoroidAI at the Heidelberg Engineering booth #3149. Experts from both Heidelberg Engineering and NetraMind Innovations will be available to showcase the application’s capabilities and answer questions from clinicians and researchers.
For more information, visit https://netramindinnovations.com/
*NMI-ChoroidAI by NetraMind Innovations is intended solely as an assistive tool and is currently not CE-marked or cleared by the FDA for clinical use. It is not intended to replace professional medical judgment or to be used in the diagnosis, treatment, or prevention of any disease. Use of these tools in clinical decision-making must be done at the sole discretion and responsibility of the licensed healthcare provider.